Ozuriftamab vedotin

BioAtla reported Q3 2024 financial results and clinical progress, including ozuriftamab vedotin Phase 2 trial in head and neck cancer showing 9-month median overall survival, and evalstotug demonstrating tumor reduction in melanoma patients. The company received FDA guidance for potential registrational trials in 2025. Q3 net loss was $10.6M, with revenue of $11.0M from a licensing agreement. R&D expenses decreased to $16.4M from $28.4M year-over-year. Cash position of $56.5M is expected to fund operations into early 2026.

BioAtla, Inc. announced the acceptance of an abstract for an oral presentation on Evalstotug, a conditionally active anti-CTLA-4 antibody, at the Society for Melanoma Research 21st International Congress in New Orleans, October 10-13, 2024.